A novel apolipoprotein e mutation, apoe osaka (arg158 pro), in a dyslipidemic patient with lipoprotein glomerulopathy

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 6, 2011, Pages 531-535

  Mitani, Asuka ^a   Ishigami, Masato ^a   Watase, Kenji ^b   Minakata, Tamotsu ^b   Yamamura, Taku ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c BUKKYO UNIVERSITY   (Japan)

Author keywords

ApoE osaka; Apolipoprotein E; Lipoprotein glomerulopathy; Mid band

Indexed keywords

APOLIPOPROTEIN E; ARGININE; PROLINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CODON; CONTROLLED STUDY; DYSLIPIDEMIA; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; EXON; GENE SEQUENCE; GLOMERULUS CAPILLARY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; LIPOPROTEIN GLOMERULOPATHY; MALE; MICROSCOPY; NEPHROTIC SYNDROME; PACINI CORPUSCLE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN CONFORMATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AMINO ACID SUBSTITUTION; APOLIPOPROTEINS E; DNA; DYSLIPIDEMIAS; EXONS; GENOTYPE; HUMANS; KIDNEY GLOMERULUS; LIPOPROTEINS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION;

EID: 79959842684     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.7377     Document Type: Article

References (22)

1. Saito T, Matsunaga A, Oikawa S: Impact of lipoprotein glomerulopathy on the relationship between lipids and re- nal diseases. Am J Kidney Dis, 2006; 47: 199-211
2. Oikawa S, Suzuki N, Sakuma E, Saito T, Namai K, Ko-Take H, Fujii Y, Toyota T: Abnormal lipoprotein and apo- lipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis, 1991; 18: 553-558
3. Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, Hayasaka K, Kotake H, Midorikawa H, Sekikawa A, Hara S, Abe K, Toyota T, Jingami H, Nakamura H, Sasaki J: Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol, 1997; 8: 820-823
4. Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T: A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int, 1999; 56: 421-427
5. Rovin BH, Roncone D, McKinley A, Nadasdy T, Korbet SM, aSchwartz MM: APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med, 2007; 357: 2522-2524
6. Foster K, Matsunaga A, Matalon R, Saito T, Gallo G, D'agati V, Stokes MB: A rare cause of posttransplantation nephrotic syndrome. Am J Kidney Dis, 2005; 45: 1132-1138
7. Cheung CY, Chan AO, Chan YH, Lee KC, Chan GP, Lau GT, Shek CC, Chau KF, Li CS: A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J, 2009; 15: 57-60
8. Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK: Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomeru- lar binding. Am J Kidney Dis, 2006; 47: 539-548
9. Luo B, Huang F, Liu Q, Li X, Chen W, Zhou SF, Yu X: Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol, 2008; 28: 347-353
10. Kinomura M, Sugiyama H, Saito T, Matsunaga A, Sada KE, Kanzaki M, Takazawa Y, Maeshima Y, Yanai H, Makino H: A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant, 2008; 23: 751-756
11. Amenomori M, Haneda M, Morikawa J, Nishigaki I, Maeda S, Hidaka H, Kikkawa R, Shigeta Y: A case of li- poprotein glomerulopathy successfully treated with pro- bucol. Nephron, 1994; 67: 109-113
12. Mead MG and Dangerfield WG: The investigation of "mid-band" lipoproteins using polyacrylamide gel electro- phoresis. Clin Chim Acta, 1974; 51: 173-182
13. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA: Three-dimensional structure of the LDL re- ceptor-binding domain of human apolipoprotein E. Sci- ence, 1991; 252: 1817-1822
14. Utermann G, Hees M, Steinmetz A: Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinae- mia in man. Nature, 1997; 269: 604-607
15. Morganroth J, Levy RI, Fredrickson DS: The biochemi- cal, clinical, and genetic features of type III hyperlipopro- teinemia. Ann Intern Med, 1975; 82: 158-174
16. Sakatsume M, Kadomura M, Sakata I, Imai N, Kondo D, Osawa Y, Shimada H, Ueno M, Miida T, Nishi S, Araka-Wa M, Gejyo F: Novel glomerular lipoprotein deposits as-sociated with apolipoprotein E2 homozygosity. Kidney Int, 2001; 59: 1911-1918
17. Karube M, Nakabayashi K, Fujioka Y, Yoshihara K, Yama-Da A, Matsunaga A, Saito T: Lipoprotein glomerulopathy- like disease in a patient with type-hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity. Clin Exp Nephrol, 2007; 11: 174-179
18. Amatruda JM, Margolis S, Hutchins GM: Type 3 hyperli- poproteinemia with mesangial foam cells in renal glomer- uli. Arch Pathol, 1974; 98: 51-54
19. Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, Fukuda S, Takahashi K, Nakamura N, Uzawa H, Shichiri M: Effects of plasmapheresis on familial type-hyperlipoproteinemia associated with glomerular lipi- dosis, nephrotic syndrome and diabetes mellitus. Athero- sclerosis, 1990; 80: 181-189
20. Murano T, Matsumura R, Misawa Y, Ozaki H, Miyashita Y, Yoshida S, Sueioshi M, Sugiyama T, Shirai K: Interac- tion of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg 25>Cys) from a patient with lipoprotein glomerulopathy. Metabolism, 2002; 51: 201-205
21. Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, Suzuki H, Sasaki J, Sasano H, Okazaki M, Toyota T, Saito T, Yamamoto TT: Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glo- merulopathy in ApoE-deficient mice. J Biol Chem, 2000; 275: 31269-31273
22. Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, März W: Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol, 2001; 12: 524-530